- Home
- OPHC vs GANX Comparison
OPHC vs GANX Comparison
Compare OPHC & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPHC
- GANX
- Stock Information
- Founded
- OPHC 2000
- GANX 2017
- Country
- OPHC United States
- GANX United States
- Employees
- OPHC N/A
- GANX N/A
- Industry
- OPHC Major Banks
- GANX Biotechnology: Pharmaceutical Preparations
- Sector
- OPHC Finance
- GANX Health Care
- Exchange
- OPHC Nasdaq
- GANX Nasdaq
- Market Cap
- OPHC 51.8M
- GANX 51.8M
- IPO Year
- OPHC N/A
- GANX 2021
- Fundamental
- Price
- OPHC $4.58
- GANX $1.62
- Analyst Decision
- OPHC
- GANX Strong Buy
- Analyst Count
- OPHC 0
- GANX 5
- Target Price
- OPHC N/A
- GANX $8.20
- AVG Volume (30 Days)
- OPHC 10.5K
- GANX 297.9K
- Earning Date
- OPHC 08-05-2025
- GANX 08-07-2025
- Dividend Yield
- OPHC N/A
- GANX N/A
- EPS Growth
- OPHC 30.24
- GANX N/A
- EPS
- OPHC 1.33
- GANX N/A
- Revenue
- OPHC $39,980,000.00
- GANX N/A
- Revenue This Year
- OPHC N/A
- GANX N/A
- Revenue Next Year
- OPHC N/A
- GANX N/A
- P/E Ratio
- OPHC $3.46
- GANX N/A
- Revenue Growth
- OPHC 53.28
- GANX N/A
- 52 Week Low
- OPHC $3.53
- GANX $0.89
- 52 Week High
- OPHC $5.90
- GANX $3.19
- Technical
- Relative Strength Index (RSI)
- OPHC 55.23
- GANX 44.03
- Support Level
- OPHC $4.53
- GANX $1.55
- Resistance Level
- OPHC $4.70
- GANX $1.72
- Average True Range (ATR)
- OPHC 0.06
- GANX 0.13
- MACD
- OPHC 0.00
- GANX 0.00
- Stochastic Oscillator
- OPHC 42.86
- GANX 23.17
About OPHC OptimumBank Holdings Inc.
OptimumBank Holdings Inc serves as a bank holding company for OptimumBank. The Bank provides community banking services to individuals and corporate customers. Its services include demand interest-bearing and non-interest-bearing accounts, negotiable order of withdrawal accounts, money market deposit accounts, debit cards, and automated teller machines.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.